Till sidinnehåll
Inloggad som:

KER-050-D301

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

KER-050-D301
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 3
Kurativ
Företag

Studien ändrades senast av: studyjohanna (2025-05-18)

Tillbaka till listan